Key Points - Industrial Fulian (601138.SH) has not lowered its profit target for the fourth quarter [1] - Shanghai Port Bay (605598.SH) reported that its commercial aerospace and perovskite solar business account for less than 1% of its revenue, indicating a small scale and no profitability [1] - Taihong Wanli (603210.SH) plans to establish a wholly-owned subsidiary to invest 480 million yuan in the construction of an automotive body structure component production line [1] - Tongji Technology (600846.SH) announced that its subsidiary won the construction bid for the Xi'an Heshan Jinxiu Mansion project [1] - ST Zhongzhu (600568.SH) revealed that Shen Shang Group intends to transfer 100% equity of Landi Technology to Bubugao Investment for 30 million yuan [1] - Naxinwei (688052.SH) plans to repurchase shares worth between 200 million to 400 million yuan [1] - Xinghui Entertainment (300043.SH) reported that its actual controller and concerted parties plan to reduce their holdings by no more than 2.9% [1] - Cixing Co., Ltd. (300307.SZ) intends to raise no more than 300 million yuan through a private placement [3] - Zhongding Co., Ltd. (000887.SZ) announced that its controlling subsidiary has become a supplier of liquid cooling dummy loads for two domestic liquid cooling system integrators [3]

Core Insights - On November 24, several A-share listed companies disclosed their shareholding changes, with some announcing share buybacks while others reported share reductions [1][2] Summary of Buybacks - Zhongchumai's controlling shareholder plans to increase holdings between 42 million to 80 million yuan - Lege Co., Ltd.'s controlling shareholder intends to buy back shares worth 40 million to 80 million yuan - Naxinwei plans to repurchase shares valued at 200 million to 400 million yuan - Jichuan Pharmaceutical aims to buy back shares worth 25 million to 50 million yuan [2] Summary of Reductions - Zhongtian Rocket's seventh and eighth largest shareholders collectively reduced their holdings by 1.2565 million shares - Wuxian Media's shareholders plan to reduce their holdings by no more than 4.70% - Shenwei Electronics has seen recent share reductions by the National Integrated Circuit Industry Investment Fund - Zhongji Xuchuang's Wang Xiaodong has cumulatively reduced 708,600 shares at an average price of 414.24 yuan per share - Dinglong Co., Ltd.'s directors Yang Pingcai and Yao Hong plan to reduce their holdings by no more than 0.04% - Dongfang Ocean's shareholder Guoyuan Fund intends to reduce holdings by no more than 3% - Xinghui Entertainment's shareholders plan to reduce their holdings by no more than 2.90% - Zhongke Information's directors Shi Zhiming and Wang Xiaodong plan to reduce their holdings by no more than 0.11% - Hongfuyun's controlling shareholder Zhang Dingwu intends to reduce holdings by no more than 2.00% - Huifa Food's shareholder Hui Xiping plans to reduce holdings by no more than 3% - Yidian Tianxia's second largest shareholder has sold company shares during stock fluctuations - Xinlaifu's shareholder Xinlaifu Asset Management Plan intends to reduce holdings by no more than 0.83% - Huitong Co., Ltd.'s shareholder Tong'an Fund plans to reduce holdings by no more than 1% - Changjiang Materials' largest shareholder and actual controller Xiong Ying reduced 190,000 shares on November 21 - Luokai Co., Ltd.'s shareholder Tiansai Electric plans to reduce holdings by no more than 0.2684% - Yaopi Glass's shareholder China Composite Materials plans to reduce holdings by no more than 2.2619% [2]

格隆汇11月24日丨济川药业(600566.SH)公布，公司拟回购股份用于实施员工持股计划或股权激励。拟 回购资金总额不低于人民币2,500万元(含)且不超过人民币5,000万元(含)。回购价格不超过人民币38元/ 股(含)。 ...

每经AI快讯，11月24日，济川药业（600566）(600566.SH)公告称，公司计划使用自有资金以集中竞价 交易方式回购部分公司股份，资金总额不低于2500万元(含)且不超过5000万元(含)，回购价格不超过38 元/股。回购期限为自董事会审议通过之日起12个月内。本次回购的股份将用于实施员工持股计划或股 权激励。 ...

一、回购方案的审议及实施程序 公司于 2025 年 11 月 24 日召开了第十届董事会第十九次会议，审议通过了 《关于以集中竞价交易方式回购公司股份方案的议案》。根据《湖北济川药业股 证券代码： 600566 证券简称： 济川药业 公告编号： 2025-095 湖北济川药业股份有限公司 关于以集中竞价交易方式回购公司股份方案的公告 暨回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 拟回购股份的用途: 实施员工持股计划或股权激励。 拟回购资金总额: 不低于人民币 2,500 万元（含）且不超过人民币 5,000 万 元（含）。 回购期限: 自董事会审议通过本回购股份方案之日起不超过 12 个月。 回购价格：不超过人民币 38 元/股（含），该回购价格不超过董事会通过回 购股份决议前 30 个交易日公司股票交易均价的 150%。 回购资金来源：公司自有资金。 相关股东是否存在减持计划：截至董事会审议通过本次回购方案之日，公 司董事、高级管理人员、控股股东、实际控制人、持股 5%以上的股东无明 确的 ...

湖北济川药业股份有限公司 （二）本次会议通知和相关资料于 2025 年 11 月 21 日以电话和电子邮件方 式送达全体董事。 证券代码： 600566 证券简称： 济川药业 公告编号： 2025-096 第十届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （一）本次会议的召开符合《公司法》《公司章程》《董事会议事规则》的 规定。 过回购股份方案之日起不超过 12 个月；同时，董事会同意授权公司经营管理层 或其授权人士全权负责本次回购股份相关事宜。具体内容详见公司于 2025 年 11 月 25 日在上海证券交易所网站（http://www.sse.com.cn）披露的《湖北济川药 业股份有限公司关于以集中竞价交易方式回购公司股份方案的公告暨回购报告 书》。 表决结果：同意 7 票，反对 0 票，弃权 0 票。本议案获得通过。 特此公告。 湖北济川药业股份有限公司 董事会 2025 年 11 月 25 日 （三）本次会议于 2025 年 11 月 24 日在湖北济川药业股份 ...

济川药业公告，拟以2500万元-5000万元回购公司股份，回购价格不超过38元/股。 ...

Core Viewpoint - Hubei Jichuan Pharmaceutical Co., Ltd. plans to repurchase and cancel 171,800 restricted stocks from its 2022 incentive plan due to the departure of some incentive targets and unsatisfactory performance evaluations [1][2][6] Repurchase Background and Basis - The repurchase is based on the 2022 incentive plan approved on August 22, 2022, aimed at binding the interests of the core team to promote long-term development [2] - According to the plan, if an incentive target leaves or fails to meet performance standards, their unvested restricted stocks will not be released and will be repurchased at the grant price plus interest [2] Specifics of the Repurchase - The total number of restricted stocks to be repurchased is 171,800, all from the initial grant of the 2022 incentive plan [3] Repurchase Price and Funding Source - The repurchase price is set at 16.00 yuan per share, the same as the grant price, with no adjustments due to unvested status [4] - The funding for the repurchase will come entirely from the company's own funds, ensuring no significant impact on daily cash flow [4] Subsequent Arrangements - The company has opened a dedicated securities account for the repurchase and submitted the necessary applications for stock cancellation and registration [5] Compliance with Procedures - Legal opinions confirm that the repurchase has followed all necessary approval and authorization procedures, complying with relevant laws and the incentive plan [6] Market Impact - The repurchase of non-compliant shares is a common practice to maintain the integrity of the incentive plan and protect the interests of the company and its shareholders [7] - The number of shares involved is small relative to the total share capital, and the action is expected to optimize the incentive mechanism and focus on stabilizing the core team [8]

证券代码：600566 证券简称：济川药业 公告编号： 2025-093 湖北济川药业股份有限公司 关于 2022 年限制性股票与股票期权激励计划 部分限制性股票回购注销实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：湖北济川药业股份有限公司（以下简称"公司"）2025 年 9 月 9 日召开第十届董事会第十七次会议，审议通过了《关于注销部分股票期权并 回购注销部分限制性股票的议案》：（1）由于 3 名激励对象离职，根据《湖北 济川药业股份有限公司 2022 年限制性股票与股票期权激励计划》(以下简称"本 激励计划")的相关规定，拟回购注销上述激励对象已获授但尚未解除限售的首 次授予的限制性股票 6.7 万股。（2）鉴于 5 名激励对象 2022 年度个人绩效考核 不达标，按照本激励计划的规定，公司拟回购注销其已获授但尚未解除限售的首 次授予的限制性股票 10.48 万股。 本次注销股份的有关情况： | 回购股份数量（股） | 注销股份数量（股） | | 注销日期 | | | | | ...

2022 年限制性股票与股票期权激励计划 回购注销部分限制性股票事项 国浩律师（上海）事务所 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: (+86)(21) 5234 1668 传真/Fax: (+86)(21) 5234 1670 网址/Website: http://www.grandall.com.cn 二〇二五年十一月 关于湖北济川药业股份有限公司 | 释 义 2 | | --- | | 律师应当声明的事项 5 | | 正 文 7 | | 一、本次激励计划回购注销事项的批准和授权 7 | | 二、本次回购注销的具体情况 9 | | 三、结论意见 10 | 国浩律师（上海）事务所 法律意见书 释 义 在本法律意见书中，除非上下文另作解释，否则下列简称和术语具有以下 含义： | 公司 | 指 | 湖北济川药业股份有限公司 | | --- | --- | --- | | 本次激励计划 ...